{"url_path":"/sec/iova/8-k/2026-07-02/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1425205/0001104659-26-080409-index.html","accession_number":"0001104659-26-080409","cik":"0001425205","ticker":"IOVA","issuer_name":"IOVANCE BIOTHERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1425205/0001104659-26-080409-index.html","primary_entity_key":"0001425205","primary_entity_name":"IOVANCE BIOTHERAPEUTICS, INC."},"word_count":301,"has_tables":true,"body_markdown":"false\n0001425205\n\n0001425205\n\n2026-06-30\n2026-06-30\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n**Current Report**\n\n \n\nPursuant to Section 13 or 15(d) of the\nSecurities Exchange Act of 1934\n\n \n\nDate of Report (date of earliest event reported):\nJune 30, 2026\n\n \n\n**IOVANCE\nBIOTHERAPEUTICS, INC.**\n\n(Exact Name of Registrant as Specified in Charter)\n\n \n\n**Delaware**\n\n**(State of Incorporation)**\n\n \n\n**001-36860**\n \n**75-3254381**\n\n**Commission File Number**\n \n**(I.R.S. Employer Identification No.)**\n\n \n \n \n\n**825\nIndustrial Road****, Suite 100**\n \n \n\n**San\nCarlos****, California**\n \n**94070**\n\n**(Address of Principal Executive Offices)**\n \n**(Zip Code)**\n\n \n \n \n\n**(650****)\n260-7120**\n\n**(Registrant’s Telephone Number, Including\nArea Code)**\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).\n\n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).\n\n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).\n\n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933\n(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth\ncompany ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\nTrading\n\nSymbol(s)\nName\nof each exchange on which\n\nregistered\n\nCommon stock, par share $0.000041666 per share\nIOVA\nThe\nNasdaq Stock Market, LLC"}